Oragenics, Inc. Regains Compliance with NYSE American
February 03 2023 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a biotech company dedicated to fighting infectious
diseases including COVID-19, today announced that the Company has
received formal notice from the NYSE American, LLC (“NYSE
American”) stating that the Company has regained compliance with
the NYSE American’s continued listing standards.
The notice the Company received from NYSE American on February
1, 2023 indicated that the Company resolved the continued listing
deficiency with respect to its low selling price as described in
Section 1003(f)(v) of the NYSE American Company Guide. The notice
further stated that the below compliance (“.BS) indicator will no
longer be disseminated and the Company has been removed from the
NYSE American noncompliant issuers on the NYSE American’s
website.
Commenting on the matter, President and CEO Ms. Kimberly Murphy
stated: “We are pleased that we have been able to quickly regain
compliance with the NYSE American’s continued listing standards as
we continue to focus on our research and development efforts.”
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases, including those caused by
coronaviruses and multidrug-resistant organisms. Its lead product
is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19
and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program
leverages coronavirus spike protein research licensed from the
National Institutes of Health (NIH) and the National Research
Council of Canada (NRC) with a focus on reducing viral transmission
and offering a more patient-friendly intranasal administration. Its
lantibiotics program features a novel class of antibiotics against
bacteria that have developed resistance to commercial antibiotics.
For more information about Oragenics, please visit
www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of its vaccine candidate and lantibiotics candidate
under the timelines and in accord with the milestones it projects;
the Company’s ability to obtain funding, non-dilutive or otherwise,
for the development of the vaccine and lantibiotic product
candidates, whether through its own cash on hand, or another
alternative source; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to vaccines and lantibiotics, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the potential application of our vaccine candidate to variants and
other coronaviruses; the Company’s ability to obtain, maintain and
enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments and demand for
vaccines and antibiotics; the Company’s expectations as to the
outcome of preclinical studies, nasal administration, transmission,
manufacturing, storage and distribution; other potential adverse
impacts due to the global COVID-19 pandemic, such as delays in
regulatory review, interruptions to manufacturers and supply
chains, adverse impacts on healthcare systems and disruption of the
global economy; the ability to sustain compliance with our listing
requirements; and general economic and market conditions and risks,
as well as other uncertainties described in our filings with the
U.S. Securities and Exchange Commission. All information set forth
in this press release is as of the date hereof. You should consider
these factors in evaluating the forward-looking statements included
in this press release and not place undue reliance on such
statements. We do not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as
a result of new information, future developments or otherwise,
should circumstances change, except as otherwise required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230203005146/en/
Oragenics, Inc. Kimberly Murphy, Chief Executive Officer
Tel: 813-286-7900 kmurphy@oragenics.com
or
LHA Investor Relations Tirth T. Patel Tel: 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Dec 2023 to Dec 2024